Research Topics
Species | Paul F RobbinsSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapyPaul F Robbins
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol 173:7125-30. 2004....- Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functionsPaul F Robbins
Surgery Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
J Immunol 180:6116-31. 2008.... - Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1Paul F Robbins
National Institutes of Health, National Cancer Institute, Surgery Branch, Bethesda, MD 20892 1201, USA
J Clin Oncol 29:917-24. 2011.... - Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functionsMarybeth S Hughes
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Hum Gene Ther 16:457-72. 2005..TCR-transduced T-cells are thus attractive candidates for evaluation in cell transfer therapies of patients with cancer... - Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanomaPaul F Robbins
Surgery Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 2B42, Bethesda, MD 20892-7502, USA
J Immunol 169:6036-47. 2002..These observations provide an impetus to develop strategies directed toward generating HLA class II-restricted tumor-reactive T cells... - Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell linesYangbing Zhao
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol 174:4415-23. 2005..These results strongly support the idea that redirection of normal T cell specificity by TCR gene transfer can have potential applications in tumor adoptive immunotherapy... - High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigensRichard A Morgan
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol 171:3287-95. 2003..These results suggest that lymphocytes genetically engineered to express anti-gp100 TCR may be of value in the adoptive immunotherapy of patients with melanoma... - Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanomaSteven A Rosenberg
Center for Cancer Research, Surgery Branch, National Cancer Institute, National Institute of Health, Building 10, Room 2B42, 10 Center Drive, Bethesda, Maryland 20892, USA
J Immunother 26:385-93. 2003.... - Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expressionJennifer A Wargo
Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Cancer Immunol Immunother 58:383-94. 2009..These results have relevance for TCR-based gene therapies targeting common epithelial malignancies... - Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapyJuhua Zhou
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunother (1997) 28:53-62. 2005.... - Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapyJianping Huang
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol 176:7726-35. 2006..004) with the ability of these TILs to mediate tumor regression following adoptive transfer... - Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant proteinMaria R Parkhurst
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1502, USA
J Immunother 27:79-91. 2004..These results suggest that recombinant tumor-associated proteins may be clinically applicable for the generation of CD4+ T helper cells in active vaccination strategies or adoptive cellular immunotherapies... - Bcl-2 overexpression enhances tumor-specific T-cell survivalJehad Charo
Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
Cancer Res 65:2001-8. 2005..Our data suggest that adoptive immunotherapy approaches to the treatment of cancer patients may be enhanced using Bcl-2-modified tumor-reactive T cells... - Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimensMark E Dudley
Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892 1201, USA
J Clin Oncol 26:5233-9. 2008..Here, we update that study and evaluate the safety and efficacy of two increased-intensity myeloablative lymphodepleting regimens... - Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cellsMaria R Parkhurst
Surgery Branch, National Cancer Institute NIH, Bethesda, Maryland 20892, USA
Clin Cancer Res 15:169-80. 2009..To develop an immunotherapy for patients with cancers that overexpress CEA, we isolated and genetically modified a T-cell receptors (TCRs) that specifically bound a CEA peptide on human cancer cells... - Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapyKhoi Q Tran
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
J Immunother 31:742-51. 2008.... - Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1Christopher E Touloukian
National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol 170:1579-85. 2003..Thus, the tumor-bearing state reverses, in part, the tolerance of T cells that results from the normal expression of tissue differentiation Ags... - Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytesMark E Dudley
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20902, USA
Science 298:850-4. 2002..This approach presents new possibilities for the treatment of patients with cancer as well as patients with human immunodeficiency virus-related acquired immunodeficiency syndrome and other infectious diseases... - Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2Bianca Heemskerk
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Hum Gene Ther 19:496-510. 2008..In this study, insertion of the IL-2 gene into antitumor TILs increased their ability to survive after IL-2 withdrawal in vitro but did not increase their in vivo persistence or clinical effectiveness... - Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regressionJianping Huang
Surgery Branch, National Cancer Institute, National Institute of Health, Bethesda, Maryland 20892, USA
J Immunother (1997) 28:258-67. 2005.... - Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapySteven A Rosenberg
Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA
Clin Cancer Res 17:4550-7. 2011..We investigated the ability of adoptive cell transfer utilizing autologous tumor-infiltrating lymphocytes (TIL) to mediate durable complete regressions in heavily pretreated patients with metastatic melanoma... - Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanomaJuhua Zhou
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol 173:7622-9. 2004..A similar analysis may also be useful for monitoring autoimmune responses... - Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 geneCary Hsu
Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Blood 109:5168-77. 2007..It does not appear that the retroviral vector integration sites played a role in the continuous growth of this cell clone, but this remains under investigation... - Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytesLaura A Johnson
Surgery Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
J Immunol 177:6548-59. 2006..We propose that inducing expression of this highly avid TCR in patient PBMC has the potential to induce tumor regression, as an "off-the-shelf" reagent for allogeneic melanoma patient gene therapy... - T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene productJianping Huang
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol 172:6057-64. 2004.... - Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bondCyrille J Cohen
Surgery Branch, Center for Cancer Research, National Cancer Institute NIH, 10 Center Drive, Bethesda, MD 20892, USA
Cancer Res 67:3898-903. 2007..Preferential pairing of cysteine-modified receptor chains accounts for these observations, which could have significant implications for the improvement of TCR gene therapy... - Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapyChristian S Hinrichs
National Cancer Institute, Bethesda, MD, USA
Blood 117:808-14. 2011..Thus, these data suggest that naive cells resist terminal differentiation, or "exhaustion," maintain high replicative potential, and therefore may be the superior subset for use in adoptive immunotherapy... - MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cellsJ Mark Sloan
Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Cancer Gene Ther 9:946-50. 2002..This study describes the simultaneous presentation of a tumor-associated antigen to both CD4(+) and CD8(+) T cells and lends support to the use of gene-modified DCs as a means to initiate both CD4(+) and CD8(+) antitumor responses... - T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitisMaria R Parkhurst
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Mol Ther 19:620-6. 2011..It also emphasizes the destructive power of small numbers of highly avid T cells and the limitations of using CEA as a target for cancer immunotherapy... - Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine designGang Zeng
Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
Cancer Res 62:3630-5. 2002..Dual-specific peptides containing both cytotoxic T-cell and helper T-cell epitopes may represent an attractive strategy of vaccine design aimed at generating tumor-reactive CD4+ and CD8+ T cells... - Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomeraseMaria R Parkhurst
National Cancer Institute, Surgery Branch and National Heart, Lung, and Blood Institute, Hematology Branch, NIH, Bethesda, Maryland 20892 1502, USA
Clin Cancer Res 10:4688-98. 2004..Therefore, we initiated a clinical protocol to evaluate the therapeutic and immunological efficacy of this peptide... - Irradiation enhances human T-cell function by upregulating CD70 expression on antigen-presenting cells in vitroJianping Huang
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunother 34:327-35. 2011..Radiation therapy may therefore enhance T-cell activation in vivo through the CD27 pathway by virtue of its ability to upregulate the expression of CD70 on antigen-presenting cells... 
A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancerNachimuthu Chinnasamy
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol 186:685-96. 2011..On the basis of these results, a clinical trial is planned in which patients bearing a variety of tumor histologies will receive autologous PBLs that have been transduced with this optimized anti-MAGE-A3 TCR...- Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapyDaniel J Powell
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1201, USA
Blood 105:241-50. 2005.... - Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapyJuhua Zhou
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol 175:7046-52. 2005.... - Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancerXin Yao
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Blood 119:5688-96. 2012..All 5 clinical trials are registered at www.clinicaltrials.gov as NCT00001832, NCT00096382, NCT00335127, NCT00509496, and NCT00513604... - Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell functionChristopher E Touloukian
National Cancer Institute, NIH, Building 10, Room 2B42, Bethesda, MD 20892, USA
Cancer Res 62:5144-7. 2002..These findings indicate that antigens expressed by malignant melanoma cells can partially activate CD4(+) T lymphocytes... - Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytesCristina Maccalli
Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892 1502, USA
Cancer Res 63:6735-43. 2003..Therefore, this alteration may either affect the localization or the processing of this gene product, which may at least in part be responsible for the differential recognition of tumor and normal cells... - High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell linesYangbing Zhao
Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol 179:5845-54. 2007..Although the biological activity of these two relatively low-affinity TCRs was comparable to wild-type reactivity in CD8(+) T cells, introduction of these TCR dramatically increased the reactivity of CD4(+) T cells to tumor cell lines... - Identification of BING-4 cancer antigen translated from an alternative open reading frame of a gene in the extended MHC class II region using lymphocytes from a patient with a durable complete regression following immunotherapySteven A Rosenberg
Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 2B42, Bethesda, MD 20892, USA
J Immunol 168:2402-7. 2002..Overexpression was not found in normal tissues or other tumor types. Thus, BING-4 represents another candidate Ag for possible use in the immunotherapy of patients with melanoma... 
Contrasting effects of FLIPL overexpression in human T cells on activation-induced cell death and cytokine productionJehad Charo
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
J Leukoc Biol 81:1297-302. 2007..The multiple effects of FLIPL indicate that this protein may influence T cell responses to antigenic stimulation...- Clonal persistence and evolution during a decade of recurrent melanomaEna Wang
Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
J Invest Dermatol 126:1372-7. 2006..Thus, metastatic melanoma recurs from a common progenitor cell and phenotypic changes occur around a central core of genetic stability. This observation may bear significance for the development of targeted anticancer therapies... - NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosisJin Ping Lai
Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, MD 20892, USA
Mod Pathol 25:854-8. 2012..Beyond its role in patient selection for targeted therapy, immunohistochemistry for NY-ESO-1 may be diagnostically useful for the distinction of synovial sarcoma from other spindle cell neoplasms... - Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinomaQiong J Wang
Authors Affiliation Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
Cancer Res 72:6119-29. 2012..Our results suggest that RCC-reactive TIL do exist in situ, but may be difficult to recover and study because of proliferative exhaustion, driven by tumor-expressed CD70. Cancer Res; 72(23); 6119-29. ©2012 AACR... - Characterization of T-cell Receptors Directed Against HLA-A*01-restricted and C*07-restricted Epitopes of MAGE-A3 and MAGE-A12Shigui Zhu
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD Ludwig Institute for Cancer Research, de Duve Institute de Duve Institute, Universite Catholique de Louvain, Brussels, Belgium
J Immunother 35:680-8. 2012..These results provide support for the use of these TCRs in cancer adoptive immunotherapy trials... - Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigenLuisa Novellino
Unit of Immunotherapy of Human Tumors and Unit of Molecular Mechanisms of Tumor Growth and Progression, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
J Immunol 170:6363-70. 2003..These findings further support the relevance of CD4(+) T cells directed against mutated epitopes in tumor immunity and provide the rationale for a possible usage of mutated, tumor-specific Ags for immunotherapy of human cancer... - Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccineXianzheng Zhou
Division of Immunology and Hematopoiesis, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
Cancer Res 65:1079-88. 2005.... - Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarkerGang Zeng
Department of Urology and Jonsson Comprehensive Cancer Center, 66 118 Center for Health Sciences, David Geffen School of Medicine at UCLA, Box 951738, Los Angeles, CA 90095, USA
Int J Cancer 114:268-73. 2005..This simple and straightforward approach may allow the investigation of the clinical significance of spontaneous Ab responses against multiple TAA and their correlation with the clinical course of malignant diseases in the future... - NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activityCristina Maccalli
Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Via Venezian 1, I-20133 Milan, Italy
Eur J Immunol 33:2033-43. 2003..Taken together these data indicate that the engagement of NKG2D, depending on the expression of its ligands by target cells, can influence the pattern of anti-tumor reactivity by T lymphocytes...